- Silo Pharma Inc (NASDAQ:SILO) entered into an agreement with Columbia University under which Silo has been granted an extension for its option to license certain assets currently under development, including Alzheimer’s disease and Stress-Induced Anxiety.
- “The first steps of our research with Columbia have been positive and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer’s therapeutic and SPC-15 for Stress Induced Anxiety disorders,” said Eric Weisblum, CEO of Silo Pharma.
- The extension to the agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center.
- Denny and her team focus on the molecular mechanisms underlying learning and memory, including Alzheimer’s disease.
- Silo is currently conducting ongoing research studies and looks forward to sharing these results as data becomes available.
- Price Action: SILO shares are trading higher by 0.68% at $5.04 on the last check Tuesday.
Enveric Biosciences Announces 1-For-50 Reverse Stock Split
Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today
